招商证券国际研报指，华润医药(03320.HK) 2025年制药业务部分实现收入510亿元人民币(下同)，按年增长10.2%。其中中药板块保持双位数增长，为年增13.0%，中药收入274亿元，中药处方药增速26.8%，远超OTC的5.6%，受益于天士力并表及心脑血管品种放量的结构性改善，这一趋势在今年有望延续。该行指，管理层未给出具体2026财年收入或利润数字指引，但在业绩会上传递以下定性信号：1...
Source Link招商证券国际研报指，华润医药(03320.HK) 2025年制药业务部分实现收入510亿元人民币(下同)，按年增长10.2%。其中中药板块保持双位数增长，为年增13.0%，中药收入274亿元，中药处方药增速26.8%，远超OTC的5.6%，受益于天士力并表及心脑血管品种放量的结构性改善，这一趋势在今年有望延续。该行指，管理层未给出具体2026财年收入或利润数字指引，但在业绩会上传递以下定性信号：1...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.